Clinical trial discovery
Find Clinical Trials
Search studies by condition, treatment, location, eligibility, or trial identifier.
Showing 1–19 of 19 trials
Active filters
Clinical trials found
Published and searchable clinical trials
Searching for clinical trials...
NCT07417800
- Conditions
- Adenocarcinoma, Adjuvant Chemoradiotherapy, Artificial Intelligent, +14 more
- Locations
-
- the Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou, Zhejiang, China
NCT06740370
- Conditions
- Adenocarcinoma, Anti-PD1 Antibody, Carcinoma, +12 more
- Locations
-
- Qunfang Zhou Beijing, None Selected, China
NCT05920863
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +14 more
- Locations
-
- 1# Banshan East Rd. Zhejiang cancer hospital Hangzhou, Zhejiang, China
Recruiting
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
NCT06333561
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
- Locations
-
- Chinese PLA General hospital Beijing, Beijing Municipality, China
NCT06609850
- Conditions
- Ablation, Adenocarcinoma, Carcinoma, +13 more
- Locations
-
- Chinese PLA General hospital Beijing, None Selected, China
NCT06632093
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, +3 more
- Locations
-
- The first hospital of China medical university Shenyang, Liaoning, China
NCT06061276
- Conditions
- Adenocarcinoma, Camrelizumab, Carcinoma, +12 more
- Locations
-
- Sun Yat-sen University Cancer Center Guanzhou, Guangdong, China
NCT06550921
- Conditions
- Ablation, Advanced Hepatocellular Carcinoma, Anti-PD1 Antibody, +2 more
- Locations
-
- Chinese PLA General hospital Beijing, None Selected, China
Recruiting
bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma
NCT06070636
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
- Locations
-
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
Recruiting
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
NCT05444478
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +17 more
- Locations
-
- Hunan Provincial People's Hospital Changsha, Hunan, China
Not Yet Recruiting
Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial
NCT07514429
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
- Locations
-
- Asan Medical Center Seoul, South Korea
Not Yet Recruiting
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
NCT07159217
- Conditions
- Biliary Tract Cancer, Biliary Tract Diseases, Biliary Tract Neoplasms, +7 more
- Locations
-
- Chinese Academy of Medical Sciences, Peking Union Medical College Hospital Beijing, China
Not Yet Recruiting
Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.
NCT05286320
- Conditions
- Lenvatinib, Pembrolizumab, Stereotactic Body Radiotherapy, +1 more
- Locations
-
- National Taiwan University Hospital Taipei, Taiawn, Taiwan
NCT06631326
- Conditions
- Adenocarcinoma, BCLC Stage C Hepatocellular Carcinoma, Carcinoma, +13 more
- Locations
-
- The first hospital of China medical university Shenyang, Liaoning, China
NCT04791176
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +16 more
- Locations
-
- Bo Chen Beijing, Beijing Municipality, China
NCT06435013
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
- Locations
-
- Cancer Center Sun Yat-sen University Guangzhou, Guangdong, China
Active, Not Recruiting
Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC Downstaging
NCT07581769
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +14 more
- Locations
-
- The First Affiiated Hospital of Sun Yat-sen University Guangzhou, Guangdong, China
- Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong, China
NCT07233759
- Conditions
- Atezolizumab, Digestive System Diseases, Digestive System Neoplasms, +7 more
- Locations
-
- National Taiwan University Hospital Taipei, Taiwan
Active, Not Recruiting
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
NCT04669496
- Conditions
- Adenocarcinoma, Carcinoma, Cholangiocarcinoma, +7 more
- Locations
-
- Zhongshan hospital Shanghai, Shanghai Municipality, China